Abstract 2685
Background
BMB are independently prognostic for survival in men with metastatic castration resistant PC. It is unclear whether prognostic or predictive value of BMB applies to an earlier HSPC state. We prospectively assessed BMB in men enrolled in S1216, a phase III trial of ADT +/- orteronel with an ultimate goal to identify HSPC patient (pt) subsets defined by BMB that have differential survival outcomes. Here we report initial results of baseline BMB from S1216 & their relationship to clinical variables.
Methods
Bone resorption [C-telopeptide(CTx) & Pyridinoline (PYD)] & formation markers [C-terminal collagen propeptide (CICP) & bone alkaline phosphatase (BAP)] were measured. Elevated BMB was defined as above median or in upper quartile for each BMB. Men were grouped as having all four, 1-3, or no BMB elevated. Frequency tables of BMB distribution across pt subsets were generated. To account for multiple comparisons, a p-value of < 0.001 was considered potentially significant.
Results
Of 1,313 men, 799 had baseline BMB. Pt characteristics [median (range) or n (%)]: age 67y (19-92); PSA 29 ng/dL (2-6710); Gleason >7: n = 479 (64%); bone mets: 604 (76%); bisphos/denosumab: 44 (5.5%); Zubrod PS 0: 547 (68%); & minimal disease extent: 389 (49%). Median BMB: CTx 0.46 ng/mL (0.03-12.2); PYD 1.68 nmol/L (0.35-17.5); CICP 116 ng/mL (0.25-3360); BAP 1.66 u/L (0-1001). At least one BMB was > median in 87% & in top quartile in 57%. In 604 w/ bone mets, 540 had at least 1 BMB > median while distribution of BMB elevation >median differed significantly w/in groups defined by PSA (p < 0.0001), Gleason score (p = 0.0001), PS (p < 0.0001) & disease extent (p < 0.0001). For example, in 292 with PSA>29, 30% had all 4 BMB elevated; in those with PSA < 29, only 6% had all 4 elevated. BMB distribution in all men did not differ within race/ethnicity, age, & bisphos/denosumab groupings. Trends were similar when BMB upper quartile was used.
Conclusions
In men with HSPC initiating ADT, at least one BMB was elevated in 87%. Differences in BMB distribution were seen within pre-defined subsets, with BMB elevation tracking with higher tumor grade, disease burden & lower PS. Assessment of BMB association with patient outcomes is planned.
Clinical trial identification
SWOG S1216; NCT01809691.
Legal entity responsible for the study
SWOG.
Funding
NIH/NCI grants CA180888, CA180819; and Millennium Pharmaceuticals (Takeda Oncology Company) NIH.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract